Skip to main content
SpringerLink
Log in
Book cover

Renal Cell Cancer pp 53–67Cite as

Prognostic Factors: Markers

  • Chapter

  • 1031 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen HT, McGovern FJ. Renal cell carcinoma. N Engl J Med 353:23, 2477, 2005.

    Google Scholar 

  2. Lane BR, Kattan GW. Predicting outcomes in renal cell carcinoma. Curr Opin Urol 15, 289–297, 2005.

    Article  PubMed  Google Scholar 

  3. Van den Berg E, Dijkhuizen T, Oosterhuis JW, van Kessel AG, de Jong B, Storkel S. Cytogenetic classification of renal cell cancer. Cancer Genet Cytogenet 95, 103–107, 1997.

    Article  PubMed  Google Scholar 

  4. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8), 2530–2540, 1999.

    PubMed  CAS  Google Scholar 

  5. Zhou M, Rubin MA. Molecular markers for renal cell carcinoma: impact on diagnosis and treatment. Semin Urol Oncol 19(2), 80–87, 2001.

    PubMed  CAS  Google Scholar 

  6. Bui MH, Zisman A, Pantuck AJ, Han KR, Wieder J, Belldegrun AS. Prognostic factors and molecular markers for renal cell carcinoma. Expert Rev Anticancer Ther 1(4), 565–575, 2001.

    Article  PubMed  CAS  Google Scholar 

  7. Srigley JR, Hutter RVP, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM. Current prognostic factors—-renal cell carcinoma. Cancer 80, 981–986, 1997.

    Article  Google Scholar 

  8. Carroll PR, Murthy VVS, Reuter V, Jhanwar S, Fair WR, Whitmore WF, Chaganti RSK. Abnormalities at chromosome region 3p12–14 characterize clear cell renal cell carcinoma. Cancer Genet Cytogenet 26, 253–259, 1987.

    Article  PubMed  CAS  Google Scholar 

  9. Yoshida MA, Ohyashiki K, Ochi H, Gibas Z, Pontes JE, Prout GR, Huben R, Sandberg AA. Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res 46, 2139–2147, 1986.

    PubMed  CAS  Google Scholar 

  10. Kovacs G, Erlandsson R, Boldog F, Ingvarsson S, Muller-Brechlin R, Klein G, Sumegi J. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85, 1571–1575, 1988.

    Article  PubMed  CAS  Google Scholar 

  11. Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, Storkel S, Kovacs A, Kovacs G. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe RCC revealed by comparative genomic hybridization. Am J Pathol 145(2), 356–364, 1994.

    PubMed  CAS  Google Scholar 

  12. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 22(8), 533–540, 2003.

    Article  PubMed  CAS  Google Scholar 

  13. Bonsib SM. Risk and prognosis in renal neoplasms, a pathologist’s perspective. Urol Clin NA 26(3), 643–660, 1999.

    Article  CAS  Google Scholar 

  14. Abou-Rebyeh H, Borgmann V, Nagel R, Al-Abadi H. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer 92(9), 2280–2285, 2001.

    Article  PubMed  CAS  Google Scholar 

  15. Grignon DJ, Ayala AG, el-Naggar A, et al. Renal cell carcinoma: a clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer 64, 2133, 1989.

    Article  PubMed  CAS  Google Scholar 

  16. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication, and targeted molecular therapy. J Urol 173, 1853–1862, 2005.

    Article  PubMed  Google Scholar 

  17. Bui MH, Selgson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9, 802, 2003.

    PubMed  CAS  Google Scholar 

  18. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93, 10595–10599, 1996.

    Article  PubMed  CAS  Google Scholar 

  19. Atkins M, McDermott D, Mier J, Stanbridge E, Youmans A, Polivy A, et al. Carbonic anhydrase IX expression predicts for renal cell cancer patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 23, 383, abstract 4512, 2004.

    Google Scholar 

  20. Pich A, Chiusa L, Margaria E. Prognostic relevance of AgNORs in tumor pathology. Micron 31(2), 133–141, 2000.

    Article  PubMed  CAS  Google Scholar 

  21. Gelb AB. Renal cell carcinoma: current prognostic factors. Cancer 80, 981–986, 1997.

    Article  PubMed  CAS  Google Scholar 

  22. Yang AH, Wang TY, Liu HC. Comparative study of the prognostic value of nuclear grade and silver binding nucleolar region in renal cell carcinoma. J Pathol 166(2), 157–161, 1992.

    Article  PubMed  CAS  Google Scholar 

  23. Joachum W, Schroder S, al-Taha R, et al. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinoma. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer 77(3), 514–521, 1996.

    Article  Google Scholar 

  24. Onda H, Yasuda M, Serizawa A, Osamura RY, Kawamura N. Clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen and tumor size. Oncol Rep 6(5), 1039–1043, 1999.

    PubMed  CAS  Google Scholar 

  25. Rioux-Leclerq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 55(4), 501–505, 2000.

    Article  Google Scholar 

  26. Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer 80(9), 1768–1775, 1997.

    Article  PubMed  CAS  Google Scholar 

  27. Lehmann J, Retz M, Nurnberg N, Schnockel U, Raffenberg U, Krams M, Kellner U, Siemer S, Weicher-Jacobsen K, Stockle M. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 101, 1552–1562, 2004.

    Article  PubMed  Google Scholar 

  28. Morell-Quadreny L, Clar-Blanch F, Fenollosa-Enterna B, Perez-Bacete M, Martinez-Lorente A, Llombart-Bosch A. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res 18(1B), 677–682, 1998.

    PubMed  CAS  Google Scholar 

  29. Moch H, Sauter G, Gasser TC, Buchholz N, Bubendorf L, Richter J, Jiang F, Dellas A, Mihatsch MJ. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 25 Suppl 1, S25–30, 1997.

    Article  PubMed  CAS  Google Scholar 

  30. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 55(3), 658–662, 1995.

    PubMed  CAS  Google Scholar 

  31. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ. P53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173, 725–728, 2005.

    Article  PubMed  CAS  Google Scholar 

  32. Skolarikos A, Alivizatos G, Bamias A, Mitropoulos D, Ferakis N, Deliveliotis C, Dimopoulos M-A. Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis? Int J Urol 12, 563–569, 2005.

    Article  PubMed  CAS  Google Scholar 

  33. Shalitin C, Epelbaum R, Moskovitz B, Segal R, Valansi C, Werner M, et al. Increased levels of a 21 kDa protein in the circulation of tumor-bearing protein. Cancer Detect Prev 18, 357–365, 1994.

    PubMed  CAS  Google Scholar 

  34. Yoshino S, Kato M, Ohada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol 2, 156–160, 1995.

    Article  PubMed  CAS  Google Scholar 

  35. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 46(1), 27–30, 1995.

    Article  PubMed  CAS  Google Scholar 

  36. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin N Am 30, 467–480, 2003.

    Article  Google Scholar 

  37. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 166, 1611–1623, 2001.

    Article  PubMed  CAS  Google Scholar 

  38. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic factors for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 165, 1090–1095, 2000.

    Google Scholar 

  39. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol 171, 1810–1813, 2004.

    Article  PubMed  Google Scholar 

  40. Selli C, Hinshaw WM, Woodard BH, et al. Stratification of risk factors in renal cell carcinoma. Cancer 52, 899, 1983.

    Google Scholar 

  41. McNichols DW, Segura JW, DeWeerd JH. Renal cell carcinoma: long term survival and late recurrences. J Urol 126, 17, 1981.

    PubMed  CAS  Google Scholar 

  42. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97(12), 2995–3002, 2003.

    Article  PubMed  Google Scholar 

  43. Green LK, Ayala AG, Ro JY, Swanson DA, Grignon DJ, Giacco GG, Guinee VF. Role of nuclear grading in Stage I renal cell carcinoma. Urology 35(5), 310, 1989.

    Google Scholar 

  44. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19, 1649–1657, 2001.

    PubMed  CAS  Google Scholar 

  45. Patard JJ, Kim HL, Lam JS, Dorey FJ, et al. Use of the University of California Los Angeles Integrating Staging System to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22, 3316–3322, 2004.

    Article  PubMed  Google Scholar 

  46. Boxer RJ, Waisman J, Lieber MM, Mampaso FM, Skinner DG. Renal carcinoma: computer analysis of 96 patients treated by nephrectomy. J Urol 122, 598–601, 1979.

    PubMed  CAS  Google Scholar 

  47. Lieber MM, Tomera FM, Taylor WF, Farrow GM. Renal adenocarcinoma in young adults: survival and variables affecting prognosis. J Urol 125, 164–168, 1981.

    PubMed  CAS  Google Scholar 

  48. Chasan SA, Pothel LR, Huben RP. Management and prognostic significance of hypercalcemia in renal cell carcinoma. Urology 33(3), 167–170, 1989.

    Article  PubMed  CAS  Google Scholar 

  49. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173, 48–51, 2005.

    PubMed  Google Scholar 

  50. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J Urol 168, 2395–2400, 2002.

    Article  PubMed  Google Scholar 

  51. Bell ET. A classification of renal tumors with observations on the frequency of the various types. J Urol 39, 238, 1938.

    Google Scholar 

  52. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Pathol 6, 655, 1982.

    CAS  Google Scholar 

  53. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 61, 1639–1651, 1988.

    Article  PubMed  CAS  Google Scholar 

  54. Thrasher JB, Paulson DB. Prognostic factors in renal cancer. Urol Clin NA 20, 247, 1993.

    CAS  Google Scholar 

  55. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 171, 598–601, 2004.

    Article  PubMed  Google Scholar 

  56. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun A. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 171, 588–591, 2004.

    Article  PubMed  Google Scholar 

  57. Fergany AF, Hafez KS, Novick AC. Long term results of nephron sparing surgery for localized renal cell carcinoma: 10 year follow up. J Urol 163, 442, 2000.

    Article  PubMed  CAS  Google Scholar 

  58. Bassil B, Dorsetz DE, Prout GR. Validation of the tumor, nodes, and metastasis classification of renal cell carcinoma. J Urol 134, 450–454, 1985.

    PubMed  CAS  Google Scholar 

  59. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology 27(4), 291–301, 1986.

    Article  PubMed  CAS  Google Scholar 

  60. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer 89(3), 604–614, 2000.

    Article  PubMed  CAS  Google Scholar 

  61. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long term results and prognostic factors. J Urol 143, 468–474, 1990.

    PubMed  CAS  Google Scholar 

  62. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han K, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169, 2076–2083, 2003.

    Article  PubMed  Google Scholar 

  63. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MW. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 166, 68–72, 2001.

    Article  PubMed  CAS  Google Scholar 

  64. Libertino JA, Zinman L, Watkins E. Long term results of resection of renal cell cancer with extension into inferior vena cava. J Urol 137, 21–24, 1987.

    PubMed  CAS  Google Scholar 

  65. Skinner DG, Pfister RF, Colvin R. Extension of renal cell carcinoma into the vena cava: the rationale for aggressive surgical management. J Urol 107, 711, 1972.

    PubMed  CAS  Google Scholar 

  66. Skinner DG, Vermilion CD, Colvin RB. The surgical management of renal cell carcinoma. J Urology 107, 705, 1972.

    CAS  Google Scholar 

  67. Siminovitch JM, Montie JE, Straffon RA. Prognostic indicators in renal adenocarcinoma. J Urol 130, 20, 1983.

    PubMed  CAS  Google Scholar 

  68. Maldazys JD, de Kernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 136, 376–379, 1986.

    PubMed  CAS  Google Scholar 

  69. Uzzo RG, Cherullo EE, Myles J, Novick AC. Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol 167, 2392, 2002.

    Article  PubMed  Google Scholar 

  70. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 170(3), 768–772; discussion 772, 2003.

    Article  PubMed  Google Scholar 

  71. Kearney GP, Waters WB, Klein LA, Richie JP, Gittes RF. Results of inferior vena cava resection for renal cell carcinoma. J Urol 125, 679, 1981.

    Google Scholar 

  72. Sogani PC, Herr HW, Rains MS, Whitmore WF. Renal cell carcinoma extending into inferior vena cava. J Urol 130, 660–663, 1983.

    PubMed  CAS  Google Scholar 

  73. Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol 59, 390–395, 1987.

    Article  PubMed  CAS  Google Scholar 

  74. Swierzewski DJ, Swierzewski MJ, Libertino JA. Radical nephrectomy in patients with renal cell carcinoma with venous, vena caval, and atrial extension. Am J Surg 168(2), 205–209, 1994.

    Article  PubMed  CAS  Google Scholar 

  75. Hatcher PA, Anderson EE, Paulson DF, Carson CC, Robertson JE. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 145, 20–24, 1991.

    PubMed  CAS  Google Scholar 

  76. Skinner DG, Pritchett TR, Lieskovsky G, Boyd SD, Stiles QR. Vena caval involvement by renal cell carcinoma. Ann Surg 210(3), 387–394, 1989.

    Article  PubMed  CAS  Google Scholar 

  77. Sosa RE, Muecke EC, Vaughan ED, McCarron JP. Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol 132, 1097–1100, 1984.

    PubMed  CAS  Google Scholar 

  78. Nesbitt JC, Soltero ER, Cinney CPN, Walsh GL, Schrump DS, Swanson DA, Pisters LL, Willis KD, Putnam JB. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg 63, 1592–1600, 1997.

    Article  PubMed  CAS  Google Scholar 

  79. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun A. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 171, 588–591, 2004.

    Article  PubMed  Google Scholar 

  80. Naitoh J, Kaplan A, Dorey F, Figlin R, Belldegrun A. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy, and postoperative immunotherapy. J Urol 162, 46–50, 1999.

    Article  PubMed  CAS  Google Scholar 

  81. Suggs WD, Smith RB, Dodson TF, Salam AA, Graham SD. Renal cell carcinoma with inferior vena caval involvement. J Vasc Surg 14, 413–418, 1991.

    Article  PubMed  CAS  Google Scholar 

  82. Lang H, Lindner V, de Fromont M, Molinie V, Letourneux H, Meyer N, Martin M, Jacqmin D. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma. Cancer 103(3), 625–629, 2005.

    Article  PubMed  Google Scholar 

  83. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer; 76, 2543–2549, 1995.

    Article  PubMed  CAS  Google Scholar 

  84. Mian BM, Bhadkamkar N, Slaton JW, Pisters PWT, Daliani D, Swanson DA, Pisters LL. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167, 65–70, 2002.

    Article  PubMed  Google Scholar 

  85. Pound CR, Partin AW, Epstein JI, Simons JW, Marshall FF. Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. Urology 42(3), 243–248, 1993.

    Article  PubMed  CAS  Google Scholar 

  86. Carducci MA, Piatadosi M, Pound CR, Epstein JI, Simons JW, Marshall FF, Partin AW. Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 53(1), 44–49, 1999.

    Article  PubMed  CAS  Google Scholar 

  87. Boczko S, Fromowitz FB, Bard RH. Papillary adenocarcinoma of kidney. A new perspective. Urology 14(5), 491–495, 1979.

    Article  PubMed  CAS  Google Scholar 

  88. Mydlo JH, Bard RH. Analysis of papillary renal adenocarcinoma. Urology 30(6), 529–534, 1987.

    Article  PubMed  CAS  Google Scholar 

  89. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma. A clinical, radiologic, and pathologic study of 34 cases. Cancer 38, 2469–2480, 1976.

    Article  PubMed  CAS  Google Scholar 

  90. Renshaw AA, Henske EP, Loughlin KR, Shapiro C, Weinberg DS. Aggressive variants of chromophobe renal cell carcinoma. Cancer 78(8), 1756–1761, 1996.

    Article  PubMed  CAS  Google Scholar 

  91. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clincopathological features of 50 cases. J Urol 154, 964–967, 1995.

    Article  PubMed  CAS  Google Scholar 

  92. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms. Am J Surg Pathol 26(3), 281–291, 2002.

    Article  PubMed  Google Scholar 

  93. Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diag Pathol 15(1), 54–67, 1998.

    CAS  Google Scholar 

  94. Kennedy SM, Merino MJ, Linehan WM, et al. Collecting duct carcinoma of the kidney. Hum Pathol 21, 449, 1990.

    Article  PubMed  CAS  Google Scholar 

  95. Davis CJ, Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 19, 1, 1995.

    Article  PubMed  Google Scholar 

  96. Carter MD, Tha S, McLoughlin MG, Owen DA. Collecting duct carcinoma of the kidney: a case report and review of the literature. J Urol 147, 1096–1098, 1992.

    PubMed  CAS  Google Scholar 

  97. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 174, 1759–1763, 2005.

    Article  PubMed  Google Scholar 

  98. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MHT, Liu X, Horvath S, Figlin RA, Belldegrun AS. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 103, 2517–2525, 2005.

    Article  PubMed  CAS  Google Scholar 

  99. Sengupta S, Lohse CM, Leibovich BL, Frank I, Thomson RH, Webster WS, Zincke H, Blute ML, Chevile JC, Kwon ED. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 104, 511–520, 2005.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Benjamin I. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Libertino
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Academic Medical Center University Hospital, Amsterdam, The Netherlands

    Jean J.M.C.H. de la Rosette MD,PhD (Chairman) (Chairman)

  2. Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy

    Cora N. Sternberg MD,FACP (Chairman) (Chairman)

  3. Department of Urology, University Hospital of Katholieke Universiteit Leuven, Leuven, Belgium

    Hein P.A. van Poppel MD,PhD (Chairman) (Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Chung, B.I., Libertino, J.A. (2008). Prognostic Factors: Markers. In: Rosette, J.J.d., Sternberg, C.N., Poppel, H.P.v. (eds) Renal Cell Cancer. Springer, London. https://doi.org/10.1007/978-1-84628-763-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-763-3_5

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-385-7

  • Online ISBN: 978-1-84628-763-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation